Nivolumab: beside a new treatment under test
581 studies: a new drug, cell therapy or vaccine is what the study tests. Page 3 of 6. Open to participants first (106), then studies with results posted, then the rest; newest registration first within each.
- An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced CancerTerminatedNCT03351231Phase 1/2Results postedHow we knowReport a problem
- A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)TerminatedNCT03347123Phase 1/2Results postedHow we knowReport a problem
- Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNActive, not recruitingNCT03341936Phase 2Results postedHow we knowReport a problem
- A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerCompletedNCT03336216Phase 2Results postedHow we knowReport a problem
- An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaCompletedNCT03329846Phase 3Results postedHow we knowReport a problem
- A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2Results postedHow we knowReport a problem
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedNCT03310619Phase 1/2Results postedHow we knowReport a problem
- A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic MelanomaTerminatedNCT03301636Phase 2Results postedHow we knowReport a problem
- Adoptive Cell Therapy Across Cancer DiagnosesCompletedNCT03296137Phase 1/2Results postedHow we knowReport a problem
- TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian CancerCompletedNCT03287674Phase 1/2Results postedHow we knowReport a problem
- Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS MutationCompletedNCT03271047Phase 2Results postedHow we knowReport a problem
- Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a MelanomaTerminatedNCT03259425Phase 2Results postedHow we knowReport a problem
- A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsTerminatedNCT03251924Phase 1/2Results postedHow we knowReport a problem
- A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaCompletedNCT03250273Phase 2Results postedHow we knowReport a problem
- A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03241173Phase 1/2Results postedHow we knowReport a problem
- Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaCompletedNCT03229278Phase 1Results postedHow we knowReport a problem
- Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerCompletedNCT03215810Phase 1Results postedHow we knowReport a problem
- Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersCompletedNCT03190174Phase 1/2Results postedHow we knowReport a problem
- A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsCompletedNCT03184870Phase 1/2Results postedHow we knowReport a problem
- Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLCCompletedNCT03181308Phase 1Results postedHow we knowReport a problem
- A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has SpreadCompletedNCT03158272Phase 1Results postedHow we knowReport a problem
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results postedHow we knowReport a problem
- CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabCompletedNCT03123783Phase 1/2Results postedHow we knowReport a problem
- First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT03110107Phase 1/2Results postedHow we knowReport a problem
- A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT03071094Phase 1/2Results postedHow we knowReport a problem
- Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & LymphomaCompletedNCT03061188Phase 1Results postedHow we knowReport a problem
- Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic MelanomaCompletedNCT03047928Phase 1/2Results postedHow we knowReport a problem
- Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasActive, not recruitingNCT03038672Phase 2Results postedHow we knowReport a problem
- A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerTerminatedNCT03026166Phase 1/2Results postedHow we knowReport a problem
- Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerCompletedNCT03015740Phase 1/2Results postedHow we knowReport a problem
- Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable CancerTerminatedNCT03009058Phase 1/2Results postedHow we knowReport a problem
- A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedNCT02996110Phase 2Results postedHow we knowReport a problem
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsCompletedNCT02983045Phase 1/2Results postedHow we knowReport a problem
- H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other GliomasCompletedNCT02960230Phase 1/2Results postedHow we knowReport a problem
- Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerTerminatedNCT02954991Phase 2Results postedHow we knowReport a problem
- A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results postedHow we knowReport a problem
- PROSTVAC in Combination With Nivolumab in Men With Prostate CancerCompletedNCT02933255Phase 1/2Results postedHow we knowReport a problem
- Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaTerminatedNCT02923531Phase 1/2Results postedHow we knowReport a problem
- A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCompletedNCT02913313Phase 1/2Results postedHow we knowReport a problem
- JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsCompletedNCT02904226Phase 1/2Results postedHow we knowReport a problem
- Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT02864381Phase 2Results postedHow we knowReport a problem
- Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction AdenocarcinomaTerminatedNCT02862535Phase 1Results postedHow we knowReport a problem
- A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02859324Phase 1/2Results postedHow we knowReport a problem
- Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerTerminatedNCT02846792Phase 1/2Results postedHow we knowReport a problem
- A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT02834247Phase 1Results postedHow we knowReport a problem
- Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaTerminatedNCT02831933Phase 2Results postedHow we knowReport a problem
- A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver CancerTerminatedNCT02828124Phase 1/2Results postedHow we knowReport a problem
- TG4010 and Nivolumab in Patients With Lung CancerCompletedNCT02823990Phase 2Results postedHow we knowReport a problem
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02771626Phase 1/2Results postedHow we knowReport a problem
- An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabCompletedNCT02754141Phase 1/2Results postedHow we knowReport a problem
- An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results postedHow we knowReport a problem
- An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT02737475Phase 1/2Results postedHow we knowReport a problem
- Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedNCT02723006Phase 1Results postedHow we knowReport a problem
- Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung CancerCompletedNCT02718066Phase 1/2Results postedHow we knowReport a problem
- An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesTerminatedNCT02712905Phase 1/2Results postedHow we knowReport a problem
- Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsCompletedNCT02705105Phase 1/2Results postedHow we knowReport a problem
- PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)TerminatedNCT02702492Phase 1Results postedHow we knowReport a problem
- Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE TrialCompletedNCT02664181Phase 2Results postedHow we knowReport a problem
- A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsTerminatedNCT02663518Phase 1Results postedHow we knowReport a problem
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadCompletedNCT02658890Phase 1/2Results postedHow we knowReport a problem
- Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)TerminatedNCT02599649Phase 2Results postedHow we knowReport a problem
- An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.CompletedNCT02598960Phase 1/2Results postedHow we knowReport a problem
- Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced CancersCompletedNCT02526017Phase 1Results postedHow we knowReport a problem
- ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT02523469Phase 1/2Results postedHow we knowReport a problem
- Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid TumorsTerminatedNCT02472977Phase 1/2Results postedHow we knowReport a problem
- A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung CancerCompletedNCT02439450Phase 1/2Results postedHow we knowReport a problem
- Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid TumorsCompletedNCT02426892Phase 2Results postedHow we knowReport a problem
- A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaCompletedNCT02423343Phase 1/2Results postedHow we knowReport a problem
- Study of BMS-986158 in Subjects With Select Advanced CancersCompletedNCT02419417Phase 1/2Results postedHow we knowReport a problem
- A Study of BMS-986148 in Patients With Select Advanced Solid TumorsTerminatedNCT02341625Phase 1/2Results postedHow we knowReport a problem
- A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)CompletedNCT02327078Phase 1/2Results postedHow we knowReport a problem
- Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerTerminatedNCT02323126Phase 2Results postedHow we knowReport a problem
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedNCT02302339Phase 2Results postedHow we knowReport a problem
- RTA 408 Capsules in Patients With Melanoma - REVEALCompletedNCT02259231Phase 1/2Results postedHow we knowReport a problem
- An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's LymphomaTerminatedNCT02253992Phase 1/2Results postedHow we knowReport a problem
- BMS-986012 in Relapsed/Refractory SCLCCompletedNCT02247349Phase 1/2Results postedHow we knowReport a problem
- Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaCompletedNCT02073123Phase 1/2Results postedHow we knowReport a problem
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesCompletedNCT02061761Phase 1/2Results postedHow we knowReport a problem
- Immunotherapy Study for Patients With Stage IV MelanomaTerminatedNCT02054520Phase 2Results postedHow we knowReport a problem
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results postedHow we knowReport a problem
- An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsCompletedNCT01968109Phase 1/2Results postedHow we knowReport a problem
- A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsCompletedNCT01714739Phase 1/2Results postedHow we knowReport a problem
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasActive, not recruitingNCT07546812Phase 2How we knowReport a problem
- IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic MelanomaCompletedNCT07436390Not applicableHow we knowReport a problem
- A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced CancersSuspendedNCT07176975Phase 1How we knowReport a problem
- Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade GliomaActive, not recruitingNCT07031765Phase 1How we knowReport a problem
- Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal CancerSuspendedNCT07011550Phase 2How we knowReport a problem
- Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue SarcomaSuspendedNCT06968988Phase 1How we knowReport a problem
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung CancerCompletedNCT06799286Phase 1How we knowReport a problem
- BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Active, not recruitingNCT06773910Phase 2How we knowReport a problem
- Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell TherapyWithdrawnNCT06767956Phase 1/2How we knowReport a problem
- PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and EpendymomaSuspendedNCT06639607Phase 1/2How we knowReport a problem
- Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal CancerActive, not recruitingNCT06547385Phase 1How we knowReport a problem
- A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsActive, not recruitingNCT06544655Phase 1How we knowReport a problem
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerCompletedNCT06542731Phase 1How we knowReport a problem
- The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal CancerActive, not recruitingNCT06540261Phase 1How we knowReport a problem
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic CancerCompletedNCT06538207Phase 1How we knowReport a problem
- Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid TumorsTerminatedNCT06535009Phase 1How we knowReport a problem
- A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)Active, not recruitingNCT06534983Phase 2How we knowReport a problem
- An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic CancerActive, not recruitingNCT06532344Phase 1How we knowReport a problem